Pharmacogenomic considerations of xenograft mouse models of acute leukemia

Pharmacogenomics

Volumn 13, Issue 15, 2012, Pages 1759-1772

  Guihard, Soizic ^a   Peyrouze, Pauline ^a   Cheok, Meyling H ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

acute lymphoblastic leukemia; acute myeloid leukemia; chemotherapy response; immunodeficient mouse model; pharmacogenetics; pharmacogenomics; xenograft

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE; ANTINEOPLASTIC AGENT; ASPARAGINASE; COMBOTOX; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; GEMTUZUMAB OZOGAMICIN; GLUCOCORTICOID; HISTONE DEACETYLASE; IMMUNOTOXIN; METHOTREXATE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NILOTINIB; PANOBINOSTAT; PLERIXAFOR; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; CELL SURFACE; DNA METHYLATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE DEFICIENCY; LEUKEMOGENESIS; PHARMACOGENOMICS; PHENOTYPE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TARGET CELL; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 84869991030     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.158     Document Type: Review

References (102)

1. Ishikawa F, Yasukawa M, Lyons B et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor g chain(null) mice. Blood 106(5), 1565-1573 (2005). (Pubitemid 41208567)
2. Ito M, Hiramatsu H, Kobayashi K et al. NOD/SCID/g(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9), 3175-3182 (2002). (Pubitemid 35217065)
3. Mcdermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116(2), 193-200 (2010).
4. Agliano A, Martin-Padura I, Mancuso P et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rg null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int. J. Cancer 123(9), 2222-2227 (2008).
5. Morisot S, Wayne AS, Bohana-Kashtan O et al. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 24(11), 1859-1866 (2010).
6. Barrett DM, Seif AE, Carpenito C et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 118(15), e112-e117 (2011).
7. Lock RB, Liem N, Farnsworth ML et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99(11), 4100-4108 (2002). (Pubitemid 35332053)
8. Nijmeijer BA, Mollevanger P, Van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JH. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/ SCID mice. Exp. Hematol. 29(3), 322-329 (2001). (Pubitemid 32220124)
9. Chao MP, Alizadeh AA, Tang C et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71(4), 1374-1384 (2011).
10. Fujisaki H, Kakuda H, Shimasaki N et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69(9), 4010-4017 (2009).
11. Liu XY, Pop LM, Tsai L, Pop IV, Vitetta ES. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines. Int. J. Cancer 129(2), 497-506 (2011).
12. Tsai LK, Pop LM, Liu X, Vitetta ES. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and pre-b acute lymphoblastic leukemia cell lines. Toxins (Basel.). 3(4), 409-419 (2011).
13. Barta SK, Zou Y, Schindler J et al. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leuk. Lymphoma 53(10), 1999-2003 (2012).
14. Zhang C, Ryu YK, Chen TZ, Hall CP, Webster DR, Kang MH. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leuk. Res. 36(3), 342-349 (2012).
15. Schmitz M, Breithaupt P, Scheidegger N et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 118(7), 1854-1864 (2011).
16. Monaco G, Konopleva M, Munsell M et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 22(2), 188-201 (2004). (Pubitemid 38282634)
17. Pearce DJ, Taussig D, Zibara K et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107(3), 1166-1173 (2006). (Pubitemid 43156319)
18. Ali N, Flutter B, Sanchez Rodriguez R et al. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rg(null) mice display a t-effector memory phenotype. PLoS One 7(8), E44219 (2012).
19. Ito R, Katano I, Kawai K et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 87(11), 1654-1658 (2009).
20. Clappier E, Gerby B, Sigaux F et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208(4), 653-661 (2011).
21. Park E, Gang EJ, Hsieh YT et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 118(8), 2191-2199 (2011).
22. Le Viseur C, Hotfilder M, Bomken S et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14(1), 47-58 (2008). (Pubitemid 351885495)
23. Meyer LH, Eckhoff SM, Queudeville M et al. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell 19(2), 206-217 (2011).
24. Watanabe S, Ohta S, Yajima M et al. Humanized NOD/SCID/IL2Rg(null) mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis. J. Virol. 81(23), 13259-13264 (2007). (Pubitemid 350156965)
25. Spiegel A, Kollet O, Peled A et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 103(8), 2900-2907 (2004). (Pubitemid 38451658)
26. Cao X, Wu X, Frassica D et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc. Natl Acad. Sci. USA 108(4), 1609-1614 (2011).
27. Liem NL, Papa RA, Milross CG et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103(10), 3905-3914 (2004). (Pubitemid 38596312)
28. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 316(5824), 600-604 (2007). (Pubitemid 46683146)
29. Tsai HJ, Kobayashi S, Izawa K et al. Bioimaging analysis of nuclear factor-kB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-a-stimulated changes to the microenvironment. Cancer Sci. 102(11), 2014-2021 (2011).
30. Fabricius D, Breckerbohm L, Vollmer A et al. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia 25(7), 1111-1121 (2011).
31. Borgmann A, Baldy C, Von Stackelberg A et al. Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr. Hematol. Oncol. 17(8), 635-650 (2000).
32. Martelli MP, Pettirossi V, Thiede C et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 116(19), 3907-3922 (2010).
33. Vilas-Zornoza A, Agirre X, Abizanda G et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 26(7), 1517-1526 (2012).
34. Samuels AL, Peeva VK, Papa RA et al. Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia. BMC Genomics 11, 256 (2010).
35. Anderson K, Lutz C, Van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469(7330), 356-361 (2011).
36. Campana D, Coustan-Smith E, Manabe A et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 81(4), 1025-1031 (1993). (Pubitemid 23054841)
37. Szymanska B, Wilczynska-Kalak U, Kang MH et al. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One 7(3), E33894 (2012).
38. High LM, Szymanska B, Wilczynska-Kalak U et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol. Pharmacol. 77(3), 483-494 (2010).
39. Kang MH, Kang YH, Szymanska B et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110(6), 2057-2066 (2007). (Pubitemid 47443923)
40. Linger RM, Deryckere D, Brandao L et al. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood 114(13), 2678-2687 (2009).
41. Ranganathan P, Yu X, Na C et al. Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120(9), 1765-1773 (2012).
42. Bhadri VA, Cowley MJ, Kaplan W, Trahair TN, Lock RB. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia. BMC Genomics 12, 565 (2011).
43. Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 105(6), 2519-2526 (2005). (Pubitemid 40387054)
44. Irving JA, Minto L, Bailey S, Hall AG. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res. 65(21), 9712-9718 (2005). (Pubitemid 41541447)
45. Beesley AH, Firth MJ, Ford J et al. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br. J. Cancer 100(12), 1926-1936 (2009).
46. Teachey DT, Sheen C, Hall J et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112(5), 2020-2023 (2008).
47. Banerji V, Frumm SM, Ross KN et al. The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J. Clin. Invest. 122(3), 935-947 (2012).
48. Hu S, Niu H, Inaba H et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J. Natl Cancer Inst. 103(11), 893-905 (2011).
49. Davidsson J, Lilljebjorn H, Andersson A et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum. Mol. Genet. 18(21), 4054-4065 (2009).
50. Roman-Gomez J, Jimenez-Velasco A, Barrios M et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk. Lymphoma 48(7), 1269-1282 (2007). (Pubitemid 47079354)
51. Weeks RJ, Kees UR, Song S, Morison IM. Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia. Mol. Cancer 9, 163 (2010).
52. Tatarelli C, Linnenbach A, Mimori K, Croce CM. Characterization of the human TESTIN gene localized in the FRA7G region at 7q31.2. Genomics 68(1), 1-12 (2000).
53. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69(10), 4443-4453 (2009).
54. Nguyen T, Dai Y, Attkisson E et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin. Cancer Res. 17(10), 3219-3232 (2011).
55. Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 21(5), 1026-1034 (2007). (Pubitemid 46672080)
56. Gebhard C, Schwarzfischer L, Pham TH, Andreesen R, Mackensen A, Rehli M. Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res. 34(11), E82 (2006).
57. Ng KP, Ebrahem Q, Negrotto S et al. p53 independent epigenetic- differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 25(11), 1739-1750 (2011).
58. Sutherland MK, Yu C, Anderson M et al. 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 2(4), 440-448 (2010).
59. Pillozzi S, Masselli M, De Lorenzo E et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117(3), 902-914 (2011).
60. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111(2), 187-196 (2003). (Pubitemid 36105917)
61. Tavor S, Petit I, Porozov S et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64(8), 2817-2824 (2004). (Pubitemid 38500620)
62. Juarez J, Dela Pena A, Baraz R et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21(6), 1249-1257 (2007). (Pubitemid 46831814)
63. Kobune M, Kawano Y, Takahashi S et al. Interaction with human stromal cells enhances CXCR4 expression and engraftment of cord blood Lin(-)CD34(-) cells. Exp. Hematol. 36(9), 1121-1131 (2008).
64. Shen W, Bendall LJ, Gottlieb DJ, Bradstock KF. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp. Hematol. 29(12), 1439-1447 (2001). (Pubitemid 34007619)
65. Juarez JG, Thien M, Dela Pena A, Baraz R, Bradstock KF, Bendall LJ. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br. J. Haematol. 145(4), 491-499 (2009).
66. Yu M, Gang EJ, Parameswaran R et al. AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo. Blood Cancer J. 1(4), e14 (2011).
67. Tavor S, Eisenbach M, Jacob-Hirsch J et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 22(12), 2151-5158 (2008).
68. Liesveld JL, Bechelli J, Rosell K et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk. Res. 31(11), 1553-1563 (2007). (Pubitemid 47632788)
69. Okazawa H, Motegi S, Ohyama N et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol. 174(4), 2004-2011 (2005). (Pubitemid 40223942)
70. Jaiswal S, Jamieson CH, Pang WW et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2), 271-285 (2009).
71. Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2), 286-299 (2009).
72. Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17(2), 334-338 (2003). (Pubitemid 36266910)
73. Herrera L, Stanciu-Herrera C, Morgan C, Ghetie V, Vitetta ES. Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia. Leuk. Lymphoma 47(11), 2380-2387 (2006). (Pubitemid 44768433)
74. van Der Velden VH, Te Marvelde JG, Hoogeveen PG et al. Targeting of the CD33- calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10), 3197-3204 (2001).
75. Hamann PR, Hinman LM, Hollander I et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13(1), 47-58 (2002). (Pubitemid 34119634)
76. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19(2), 176-182 (2005). (Pubitemid 40220577)
77. Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp. Hematol. 37(6), 755-766 (2009).
78. Linenberger ML, Hong T, Flowers D et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98(4), 988-994 (2001).
79. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 103(11), 4276-4284 (2004). (Pubitemid 38685374)
80. Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood 111(9), 4813-4816 (2008).
81. Golay J, Di Gaetano N, Amico D et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128(3), 310-317 (2005). (Pubitemid 40216152)
82. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997). (Pubitemid 27298715)
83. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994). (Pubitemid 24067706)
84. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89(9), 3104-3112 (1997). (Pubitemid 27229792)
85. Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25(11), 1315-1321 (2007). (Pubitemid 350076512)
86. Eppert K, Takenaka K, Lechman ER et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17(9), 1086-1093 (2011).
87. Gerber JM, Smith BD, Ngwang B et al. A clinically relevant population of leukemic CD34+CD38-cells in acute myeloid leukemia. Blood 119(15), 3571-3577 (2012).
88. Taussig DC, Pearce DJ, Simpson C et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106(13), 4086-4092 (2005). (Pubitemid 41775913)
89. Sarry JE, Murphy K, Perry R et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgc-deficient mice. J. Clin. Invest. 121(1), 384-395 (2011).
90. Taussig DC, Vargaftig J, Miraki-Moud F et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34-fraction. Blood 115(10), 1976-1984 (2010).
91. McDermott SP, Eppert K, Notta F et al. A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood 119(5), 1200-1207 (2012).
92. Saito Y, Uchida N, Tanaka S et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28(3), 275-280 (2010).
93. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 95(3), 1007-1013 (2000). (Pubitemid 30062725)
94. Kong Y, Yoshida S, Saito Y et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22(6), 1207-1213 (2008). (Pubitemid 351833789)
95. Hong D, Gupta R, Ancliff P et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319(5861), 336-339 (2008).
96. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 104(9), 2919-2925 (2004). (Pubitemid 39434980)
97. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 113(14), 3287-3296 (2009).
98. Canale S, Cocco C, Frasson C et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 25(12), 1815-1824 (2011).
99. Jan M, Snyder TM, Corces-Zimmerman MR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4(149), 149ra118 (2012).
100. Goardon N, Marchi E, Atzberger A et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19(1), 138-152 (2011).
101. Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 10(11), 1839-1851 (2009).
102. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 6(2), 117-129 (2006). (Pubitemid 43361544)